Gilead Gilead aims to challenge GSK's HIV drug Tivicay But GSK hit back with plans for two-drug regimen.
News Can Gilead find another Pharmasset in 2017? Company needs to make acquisition to grow, admits CEO.
News New Gilead and AbbVie hepatitis C combos filed in EU Companies aim to cut treatment time and side effects.
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
